Meryem Khadija Talbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meryem Khadija Talbo has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Sophie Brazeau
School of Human Nutrition, McGill University, Montreal, QC, Canada
15 shared publications - Rémi Rabasa-Lhoret
Institut de Recherches Cliniques de Montréal, Montréal, Canada
8 shared publications - Alexandra Katz
Department of Medicine McGill University Montreal Quebec Canada
6 shared publications - Tricia M. Peters
Department of Internal Medicine McGill University Montreal Canada
4 shared publications - Zekai Wu
Department of Medicine, Division of Experimental Medicine McGill University Quebec Canada
4 shared publications - Anne Bonhoure
Montreal Clinical Research Institute, Montreal, Québec, Canada; Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada
3 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Elsevier in Diabetes & Metabolism
Automated insulin delivery and lower burden of hypoglycemia in type 1 diabetes: a prospective analysis of the BETTER registry
- 16 November 2026
- Published by Elsevier in Diabetes & Metabolism
Open AccessAutomated insulin delivery and lower burden of hypoglycemia in type 1 diabetes: a prospective analysis of the BETTER registry
- Open Access
- 24 August 2026
- Published by Elsevier in Canadian Journal of Diabetes
Prandial Insulin Adjustments in the Context of Gastroparesis and Type 1 Diabetes: A Mixed-Methods Study
- 24 August 2026
- Published by Elsevier in Canadian Journal of Diabetes
Open AccessPrandial Insulin Adjustments in the Context of Gastroparesis and Type 1 Diabetes: A Mixed-Methods Study
- Open Access
- 15 January 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (5) , 720-727
Screening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines
- 15 January 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (5) , 720-727
Open AccessScreening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines
- Open Access
- 18 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1150-1159
Despite lower haemoglobin A1c with second‐generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis
Objective: We aim to compare second‐generation automated insulin delivery systems (AIDs) with other treatment modalities regarding both glucose management outcomes and person‐reported outcomes/experiences (PROs/PREs, measured by the Hypoglycemia Fear Survey, Hypoglycemic Confidence Scale, Hyperglycemia Avoidance Scale, Diabetes Distress Scale, Pittsburgh Sleep Quality Index, Well‐being Scale, and treatment satisfaction) among adults with type 1 diabetes. Research design and methods: Cross‐sectional analysis of the Canadian BETTER type 1 diabetes registry. Adult participants were divided into five groups: second‐generation AIDs, first‐generation AIDs, continuous glucose monitoring (CGM) + pump, CGM + multiple daily injections (MDI), and non‐CGM using MDI or pump. Generalized linear models were used to assess differences between the second‐generation AID group and each of the other groups, with p < 0.05 considered significant. Results: Among 1731 participants (69.2% females), mean age was 45.3 ± 15.3 years with 24.7 ± 16.0 years of diabetes. The second‐generation AID group had the highest proportion of achieving target haemoglobin A1c ≤ 7% (58.1%) compared to 40.6% in the first‐generation AID group, 40.5% in the Pump + CGM group, 37.3% in the MDI + CGM group, and 32.3% in the non‐CGM group, even after adjustment for multiple imbalanced characteristics ( p < 0.001). While second‐generation AID users reported higher treatment satisfaction, no other differences in measures of PROs/PREs were found between second‐generation AID and other groups. Elevated diabetes distress (55%) and poor sleep quality (63%) remained common across all treatment groups, and even among those who had reached the optimal HbA1c target (48% and 60%, respectively). Conclusions: In real‐world settings, second‐generation AIDs were associated with lower haemoglobin A1c and higher treatment satisfaction but not better PROs/PREs. Mental burden remained high despite the use of advanced diabetes technologies and optimal glucose management.
- 18 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1150-1159
Open AccessDespite lower haemoglobin A1c with second‐generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis
Objective: We aim to compare second‐generation automated insulin delivery systems (AIDs) with other treatment modalities regarding both glucose management outcomes and person‐reported outcomes/experiences (PROs/PREs, measured by the Hypoglycemia Fear Survey, Hypoglycemic Confidence Scale, Hyperglycemia Avoidance Scale, Diabetes Distress Scale, Pittsburgh Sleep Quality Index, Well‐being Scale, and treatment satisfaction) among adults with type 1 diabetes. Research design and methods: Cross‐sectional analysis of the Canadian BETTER type 1 diabetes registry. Adult participants were divided into five groups: second‐generation AIDs, first‐generation AIDs, continuous glucose monitoring (CGM) + pump, CGM + multiple daily injections (MDI), and non‐CGM using MDI or pump. Generalized linear models were used to assess differences between the second‐generation AID group and each of the other groups, with p < 0.05 considered significant. Results: Among 1731 participants (69.2% females), mean age was 45.3 ± 15.3 years with 24.7 ± 16.0 years of diabetes. The second‐generation AID group had the highest proportion of achieving target haemoglobin A1c ≤ 7% (58.1%) compared to 40.6% in the first‐generation AID group, 40.5% in the Pump + CGM group, 37.3% in the MDI + CGM group, and 32.3% in the non‐CGM group, even after adjustment for multiple imbalanced characteristics ( p < 0.001). While second‐generation AID users reported higher treatment satisfaction, no other differences in measures of PROs/PREs were found between second‐generation AID and other groups. Elevated diabetes distress (55%) and poor sleep quality (63%) remained common across all treatment groups, and even among those who had reached the optimal HbA1c target (48% and 60%, respectively). Conclusions: In real‐world settings, second‐generation AIDs were associated with lower haemoglobin A1c and higher treatment satisfaction but not better PROs/PREs. Mental burden remained high despite the use of advanced diabetes technologies and optimal glucose management.
- Open Access
- 12 February 2025
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 49 (3) , 194-204
Exercise and Glycemic Management in Females and Women With Diabetes: The Role of Sex and Gender Across the Lifespan
- 12 February 2025
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 49 (3) , 194-204
Open AccessExercise and Glycemic Management in Females and Women With Diabetes: The Role of Sex and Gender Across the Lifespan
- Open Access
Strategies to Reduce Hyperglycemia-Related Anxiety in Elite Athletes with Type 1 Diabetes: A Qualitative Analysis
Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. Hyperglycemia-related anxiety (HRA) likely affects performance and diabetes management, but research is limited. This study investigates current strategies employed to mitigate HRA during competition and the development of alternative approaches. Research Design and Methods: Elite athletes with TID, aged > 14 who self-reported HRA during competition were recruited. Elite athletes were defined as individuals exercising >10 hours per week whose athletic performance has achieved the highest competition level. 60 to 90-minute virtual semi-structured interviews were analyzed using an Interpretative Phenomenological Analysis. Results: Ten elite athletes with T1D (average age 25 ± 3 years; T1D duration 12 ± 8 years; # of competitions per year 27 ± 19; training time per week 12 ± 6 hours) reported the strategies they currently use to mitigate HRA. These strategies include managing insulin and nutrition intake, embracing social support networks, using technology, practicing relaxation techniques, establishing routines, performing pre-competition aerobic exercise, and maintaining adequate sleep hygiene. Several additional approaches that could be implemented were identified including establishing targeted support networks, developing peer-reviewed resources on HRA, ensuring support teams have sufficient tools, and improving existing technology. Conclusions: Elite athletes with T1D use physiological and psychological strategies to mitigate HRA during competition. This finding highlights the need for increased support and education for these athletes, and advancements in technology. Targeted strategies and personalized approaches are also needed to optimize performance and diabetes management in this population.
Open AccessStrategies to Reduce Hyperglycemia-Related Anxiety in Elite Athletes with Type 1 Diabetes: A Qualitative Analysis
Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. Hyperglycemia-related anxiety (HRA) likely affects performance and diabetes management, but research is limited. This study investigates current strategies employed to mitigate HRA during competition and the development of alternative approaches. Research Design and Methods: Elite athletes with TID, aged > 14 who self-reported HRA during competition were recruited. Elite athletes were defined as individuals exercising >10 hours per week whose athletic performance has achieved the highest competition level. 60 to 90-minute virtual semi-structured interviews were analyzed using an Interpretative Phenomenological Analysis. Results: Ten elite athletes with T1D (average age 25 ± 3 years; T1D duration 12 ± 8 years; # of competitions per year 27 ± 19; training time per week 12 ± 6 hours) reported the strategies they currently use to mitigate HRA. These strategies include managing insulin and nutrition intake, embracing social support networks, using technology, practicing relaxation techniques, establishing routines, performing pre-competition aerobic exercise, and maintaining adequate sleep hygiene. Several additional approaches that could be implemented were identified including establishing targeted support networks, developing peer-reviewed resources on HRA, ensuring support teams have sufficient tools, and improving existing technology. Conclusions: Elite athletes with T1D use physiological and psychological strategies to mitigate HRA during competition. This finding highlights the need for increased support and education for these athletes, and advancements in technology. Targeted strategies and personalized approaches are also needed to optimize performance and diabetes management in this population.
- Open Access
- 28 August 2024
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 40 (6) , e3837
Overweight and Obesity in People Living With Type 1 Diabetes: A Cross‐Sectional Analysis of the BETTER Registry
Aims: The prevalence and associations of overweight and obesity in Canadian adult people living with type 1 diabetes (PWT1D) are poorly documented. In a cohort of PWT1D patients, this study assesses (i) overweight and obesity frequencies and associated PWT1D clinicodemographic characteristics, (ii) diabetes characteristics, and (iii) the use of noninsulin adjunctive agents.Materials and Methods: Cross‐sectional analysis of self‐reported data from the BETTER registry: 1091 adult PWT1D (aged 44.4 ± 15.0 years; 32% HbA1cp < 0.001). Compared to other PWT1D, those living with obesity reported higher HbA1c (p < 0.05), less frequent hypoglycemia (p < 0.05), more cardiovascular diseases (p < 0.003), retinopathy, neuropathy, depression treatment as well as noninsulin adjunctive agent use (all p < 0.001). Logistic regression showed that living with overweight/obesity was associated with male sex, being treated for cardiorenal therapies, depression, diabetes duration, and total daily insulin doses.Conclusions: Overweight or obesity affects over half of adult PWT1D in the Canadian BETTER registry and is associated with higher HbA1c levels, higher total daily insulin doses, more chronic diabetes complications and noninsulin adjunctive agent use, a worse cardiometabolic profile, and lower hypoglycemia frequency.
- 28 August 2024
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 40 (6) , e3837
Open AccessOverweight and Obesity in People Living With Type 1 Diabetes: A Cross‐Sectional Analysis of the BETTER Registry
Aims: The prevalence and associations of overweight and obesity in Canadian adult people living with type 1 diabetes (PWT1D) are poorly documented. In a cohort of PWT1D patients, this study assesses (i) overweight and obesity frequencies and associated PWT1D clinicodemographic characteristics, (ii) diabetes characteristics, and (iii) the use of noninsulin adjunctive agents.Materials and Methods: Cross‐sectional analysis of self‐reported data from the BETTER registry: 1091 adult PWT1D (aged 44.4 ± 15.0 years; 32% HbA1cp < 0.001). Compared to other PWT1D, those living with obesity reported higher HbA1c (p < 0.05), less frequent hypoglycemia (p < 0.05), more cardiovascular diseases (p < 0.003), retinopathy, neuropathy, depression treatment as well as noninsulin adjunctive agent use (all p < 0.001). Logistic regression showed that living with overweight/obesity was associated with male sex, being treated for cardiorenal therapies, depression, diabetes duration, and total daily insulin doses.Conclusions: Overweight or obesity affects over half of adult PWT1D in the Canadian BETTER registry and is associated with higher HbA1c levels, higher total daily insulin doses, more chronic diabetes complications and noninsulin adjunctive agent use, a worse cardiometabolic profile, and lower hypoglycemia frequency.
- Open Access
- 23 May 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (8) , e54-e56
TheSupport-ProOnline Training Platform: Increasing Health Care Professionals’ Confidence and Knowledge in Treating People Living With Type 1 Diabetes
Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla
- 23 May 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (8) , e54-e56
Open AccessTheSupport-ProOnline Training Platform: Increasing Health Care Professionals’ Confidence and Knowledge in Treating People Living With Type 1 Diabetes
Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla
- 31 January 2024
- Published by Springer Nature in Current Diabetes Reports
- Vol. 24 (4) , 61-73
Exploring Technology’s Influence on Health Behaviours and Well-being in Type 1 Diabetes: a Review
Purpose of Review Maintaining positive health behaviours promotes better health outcomes for people with type 1 diabetes (T1D). However, implementing these behaviours may also lead to additional management burdens and challenges. Diabetes technologies, including continuous glucose monitoring systems, automated insulin delivery systems, and digital platforms, are being rapidly developed and widely used to reduce these burdens. Our aim was to review recent evidence to explore the influence of these technologies on health behaviours and well-being among adults with T1D and discuss future directions. Recent Findings Current evidence, albeit limited, suggests that technologies applied in diabetes self-management education and support (DSME/S), nutrition, physical activity (PA), and psychosocial care areas improved glucose outcomes. They may also increase flexibility in insulin adjustment and eating behaviours, reduce carb counting burden, increase confidence in PA, and reduce mental burden. Summary Technologies have the potential to promote health behaviours changes and well-being for people with T1D. More confirmative studies on their effectiveness and safety are needed to ensure optimal integration in standard care practices.
- 31 January 2024
- Published by Springer Nature in Current Diabetes Reports
- Vol. 24 (4) , 61-73
Exploring Technology’s Influence on Health Behaviours and Well-being in Type 1 Diabetes: a Review
Purpose of Review Maintaining positive health behaviours promotes better health outcomes for people with type 1 diabetes (T1D). However, implementing these behaviours may also lead to additional management burdens and challenges. Diabetes technologies, including continuous glucose monitoring systems, automated insulin delivery systems, and digital platforms, are being rapidly developed and widely used to reduce these burdens. Our aim was to review recent evidence to explore the influence of these technologies on health behaviours and well-being among adults with T1D and discuss future directions. Recent Findings Current evidence, albeit limited, suggests that technologies applied in diabetes self-management education and support (DSME/S), nutrition, physical activity (PA), and psychosocial care areas improved glucose outcomes. They may also increase flexibility in insulin adjustment and eating behaviours, reduce carb counting burden, increase confidence in PA, and reduce mental burden. Summary Technologies have the potential to promote health behaviours changes and well-being for people with T1D. More confirmative studies on their effectiveness and safety are needed to ensure optimal integration in standard care practices.
- 31 January 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (2) , 136-145
Does Insulin Delivery Technology Change Our Relationship with Foods? A Scoping Review
Introduction: Automated insulin delivery (AID) systems reduce burden and improve glycemic management for people with type 1 diabetes (PwT1D) by automatically adjusting insulin as a response to measured glucose levels. There is a lack of evidence on AID and nutrition variables such as dietary intake, eating behaviors, and disordered eating. Objectives: This scoping review aims to provide a summary of the literature regarding AID and nutrition variables and to identify gaps that require further investigation. Methods: Two researchers conducted a blinded search of Medline (OVID) and PubMed for studies, including AID use (compared to non-AID use) and nutrition variables. Studies from January 2000 to July 2023 were included, as were PwT1D of all ages. Results: A total of 3132 articles were screened for appropriateness. After exclusions, 7 studies were included (2017–2023): 4 qualitative, 1 crossover, 1 randomized controlled, and 1 observational. Studies included adolescents ( n = 1), adults ( n = 3) or both ( n = 2), and all ages ( n = 1). In quantitative studies, AID was associated with lower eating distress (−0.43 ± 0.12, P = 0.004) and higher quality of life (3.1, 95% confidence interval [CI]: 0.8–5.4, P = 0.01), but not grams of carbohydrates at meals (1.0; 95% CI: −0.7 to 3.0; P = 0.24) and snacks (0.004; 95% CI: −0.8 to 0.8; P = 0.99) compared to non-AID use. In qualitative studies, AID increased the frequency and portions of food intake and led to less dietary control from parents. AID users reported eating foods higher in energy density. PwT1D were less worried about achieving accurate carbohydrate counting (CC) when using AID. Conclusions: AID use appears to influence eating behaviors, dietary patterns, and CC, although evidence was limited. AID may reduce food management burden due to the perception that AID can correct for CC inaccuracy. Significance: Further research needs to determine if AID allows for simplification of CC and improves eating behaviors while maintaining glycemic stability.
- 31 January 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (2) , 136-145
Does Insulin Delivery Technology Change Our Relationship with Foods? A Scoping Review
Introduction: Automated insulin delivery (AID) systems reduce burden and improve glycemic management for people with type 1 diabetes (PwT1D) by automatically adjusting insulin as a response to measured glucose levels. There is a lack of evidence on AID and nutrition variables such as dietary intake, eating behaviors, and disordered eating. Objectives: This scoping review aims to provide a summary of the literature regarding AID and nutrition variables and to identify gaps that require further investigation. Methods: Two researchers conducted a blinded search of Medline (OVID) and PubMed for studies, including AID use (compared to non-AID use) and nutrition variables. Studies from January 2000 to July 2023 were included, as were PwT1D of all ages. Results: A total of 3132 articles were screened for appropriateness. After exclusions, 7 studies were included (2017–2023): 4 qualitative, 1 crossover, 1 randomized controlled, and 1 observational. Studies included adolescents ( n = 1), adults ( n = 3) or both ( n = 2), and all ages ( n = 1). In quantitative studies, AID was associated with lower eating distress (−0.43 ± 0.12, P = 0.004) and higher quality of life (3.1, 95% confidence interval [CI]: 0.8–5.4, P = 0.01), but not grams of carbohydrates at meals (1.0; 95% CI: −0.7 to 3.0; P = 0.24) and snacks (0.004; 95% CI: −0.8 to 0.8; P = 0.99) compared to non-AID use. In qualitative studies, AID increased the frequency and portions of food intake and led to less dietary control from parents. AID users reported eating foods higher in energy density. PwT1D were less worried about achieving accurate carbohydrate counting (CC) when using AID. Conclusions: AID use appears to influence eating behaviors, dietary patterns, and CC, although evidence was limited. AID may reduce food management burden due to the perception that AID can correct for CC inaccuracy. Significance: Further research needs to determine if AID allows for simplification of CC and improves eating behaviors while maintaining glycemic stability.